open access

Vol 10, No 2 (2021)
Case report
Published online: 2021-02-16
Get Citation

The use of dapagliflozin in the treatment of type 1 diabetes in a 36-year-old patient

Katarzyna Rutkowska, Katarzyna Cypryk
DOI: 10.5603/DK.a2021.0013
·
Clinical Diabetology 2021;10(2):200-203.

open access

Vol 10, No 2 (2021)
Case reports
Published online: 2021-02-16

Abstract

Until recently, insulin was the only medicine used in therapy of type 1 diabetes mellitus (T1DM).As our knowledge of pathomechanisms involved in diabetes evolves, other promising drugs are being introduced, e.g. metformin in the patients with insulin resistance or sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with poor metabolic control. The first SGLT-2 inhibitor (dapagliflozin) has been recently approved by the National Institute for Health and Clinical Excellence (NICE) for additional treating of poorly controlled type 1 diabetes. This article presents a case of patient with type 1 diabetes successfully treated with insulin and dapagliflozin at a daily dose of 5 mg.

Abstract

Until recently, insulin was the only medicine used in therapy of type 1 diabetes mellitus (T1DM).As our knowledge of pathomechanisms involved in diabetes evolves, other promising drugs are being introduced, e.g. metformin in the patients with insulin resistance or sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with poor metabolic control. The first SGLT-2 inhibitor (dapagliflozin) has been recently approved by the National Institute for Health and Clinical Excellence (NICE) for additional treating of poorly controlled type 1 diabetes. This article presents a case of patient with type 1 diabetes successfully treated with insulin and dapagliflozin at a daily dose of 5 mg.

Get Citation

Keywords

diabetes mellitus type 1; dapagliflozin; continuous glucose monitoring

About this article
Title

The use of dapagliflozin in the treatment of type 1 diabetes in a 36-year-old patient

Journal

Clinical Diabetology

Issue

Vol 10, No 2 (2021)

Article type

Case report

Pages

200-203

Published online

2021-02-16

DOI

10.5603/DK.a2021.0013

Bibliographic record

Clinical Diabetology 2021;10(2):200-203.

Keywords

diabetes mellitus type 1
dapagliflozin
continuous glucose monitoring

Authors

Katarzyna Rutkowska
Katarzyna Cypryk

References (14)
  1. Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1–95.
  2. Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017; 60(9): 1594–1600.
  3. Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5(8): 597–609.
  4. Danne T, Garg S, Peters AL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019; 42(6): 1147–1154.
  5. Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018; 25(6): 467–476.
  6. Maj-Podsiadło A, Cichocka E, Gumprecht J. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes. Clinical Diabetology. 2020; 9(3): 189–192.
  7. Paik J, Blair HA, Paik J, et al. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019; 79(17): 1877–1884.
  8. Dandona P, Mathieu C, Phillip M, et al. DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018; 41(12): 2552–2559.
  9. Trojanowska-Grigoriew M, Majkowska L. Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment. Clinical Diabetology. 2016; 5(2): 66–72.
  10. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
  11. Sarraju A, Li J, Cannon CP, et al. Erratum. The relative and combined ability of high-sensitivity cardiac troponin t and n-terminal pro-b-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes care 2014;37:295-303. Diabetes Care. 2015; 38(7): 1393–1897.
  12. Berg DD, Wiviott SD, Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): 1317–1326.
  13. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42(8): 1593–1603.
  14. Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1–95.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl